IL285619A - Universal donor stem cells and related methods - Google Patents

Universal donor stem cells and related methods

Info

Publication number
IL285619A
IL285619A IL285619A IL28561921A IL285619A IL 285619 A IL285619 A IL 285619A IL 285619 A IL285619 A IL 285619A IL 28561921 A IL28561921 A IL 28561921A IL 285619 A IL285619 A IL 285619A
Authority
IL
Israel
Prior art keywords
stem cells
related methods
universal donor
donor stem
universal
Prior art date
Application number
IL285619A
Other languages
English (en)
Hebrew (he)
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of IL285619A publication Critical patent/IL285619A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
IL285619A 2019-02-15 2021-08-15 Universal donor stem cells and related methods IL285619A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201916277913A 2019-02-15 2019-02-15
US201916596697A 2019-10-08 2019-10-08
PCT/US2020/018467 WO2020168317A2 (fr) 2019-02-15 2020-02-16 Cellules souches donnatrices universelles et méthodes associées

Publications (1)

Publication Number Publication Date
IL285619A true IL285619A (en) 2021-09-30

Family

ID=72045137

Family Applications (1)

Application Number Title Priority Date Filing Date
IL285619A IL285619A (en) 2019-02-15 2021-08-15 Universal donor stem cells and related methods

Country Status (11)

Country Link
EP (1) EP3924375A4 (fr)
JP (1) JP2022526218A (fr)
KR (1) KR20210128440A (fr)
CN (1) CN113906048A (fr)
AU (1) AU2020223192A1 (fr)
BR (1) BR112021016178A2 (fr)
CA (1) CA3130398A1 (fr)
IL (1) IL285619A (fr)
MX (1) MX2021009842A (fr)
SG (1) SG11202108891QA (fr)
WO (1) WO2020168317A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4149525A1 (fr) * 2020-05-15 2023-03-22 Rxcell Inc. Cellules hypo-immunogènes et leurs utilisations dans des réponses immunitaires
CN114457021A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd47抗体的多能干细胞及其衍生物与应用
CN114525256A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达Siglec-15阻断物的多能干细胞或其衍生物及应用
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
AU2021396403A1 (en) * 2020-12-11 2023-06-29 Intellia Therapeutics, Inc. Compositions and methods for reducing mhc class ii in a cell
WO2022140587A1 (fr) * 2020-12-23 2022-06-30 Intellia Therapeutics, Inc. Compositions et procédés pour modifier génétiquement le ciita dans une cellule
CA3200509A1 (fr) 2020-12-31 2022-07-07 Sonja SCHREPFER Methodes et compositions pour moduler une activite de car-t
AU2022283291A1 (en) 2021-05-27 2023-11-02 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
CA3227613A1 (fr) 2021-08-11 2023-02-16 William Dowdle Systemes inductibles pour modifier l'expression genique dans des cellules hypoimmunogenes
WO2023122337A1 (fr) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Lymphocytes t à récepteur antigénique chimérique (car) pour le traitement d'une maladie auto-immune et méthodes associées
WO2023154578A1 (fr) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Méthodes de traitement de patients présentant une thérapie préalable ayant échoué avec des cellules hypoimmunogènes
WO2023191063A1 (fr) * 2022-04-01 2023-10-05 株式会社Logomix Cellule appropriée pour l'ingénierie génique, l'ingénierie cellulaire et la médecine cellulaire, et son procédé de production
WO2024003349A1 (fr) 2022-07-01 2024-01-04 Novo Nordisk A/S Amélioration de la différenciation neuronale de cellules progénitrices neurales du mésencéphale ventral

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3294342A4 (fr) * 2015-05-08 2018-11-07 President and Fellows of Harvard College Cellules souches de donneur universel et procédés associés
CN108368520B (zh) * 2015-11-04 2023-01-17 菲特治疗公司 多能细胞的基因组工程改造
KR20190103373A (ko) * 2017-01-13 2019-09-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능 세포

Also Published As

Publication number Publication date
KR20210128440A (ko) 2021-10-26
JP2022526218A (ja) 2022-05-24
SG11202108891QA (en) 2021-09-29
CA3130398A1 (fr) 2020-08-20
EP3924375A2 (fr) 2021-12-22
AU2020223192A1 (en) 2021-09-09
CN113906048A (zh) 2022-01-07
WO2020168317A8 (fr) 2021-02-25
WO2020168317A2 (fr) 2020-08-20
MX2021009842A (es) 2021-12-10
EP3924375A4 (fr) 2023-03-22
WO2020168317A3 (fr) 2020-10-29
BR112021016178A2 (pt) 2021-11-03

Similar Documents

Publication Publication Date Title
IL285619A (en) Universal donor stem cells and related methods
AU2021221859A1 (en) Universal donor stem cells and related methods
EP3652304A4 (fr) Cellules de donneur universel et procédés associés
EP3423564A4 (fr) Cellules microgliales dérivées de cellules souches pluripotentes et méthodes de préparation et d'utilisation de ces dernières
IL281280A (en) Universal donor cells
IL283169A (en) CRISPR-CAS12J enzyme and system
EP3334820A4 (fr) Cellules souches pluripotentes étendues et induites, procédés de fabrication et d'utilisation
IL276523A (en) Modified pluripotent stem cells and methods of preparation and use
EP3707240A4 (fr) Cellules souches et dispositifs de régénération osseuse
IL281171A (en) Cellulose-synthase-like enzymes and uses thereof
IL291044A (en) Universal donor cells
IL290504A (en) Universal donor cells
EP3591741A4 (fr) Pile rechargeable et son procédé de fabrication
EP3336176A4 (fr) Cellules souches adhésives améliorées dérivées de cordon ombilical, leur procédé de préparation, et leur utilisation
EP3299023A4 (fr) Cellule souche mésenchymateuse cultivée en hypoxie et utilisation de celle-ci
GB201701509D0 (en) Pluripotenet stem cells
EP4041255A4 (fr) Cellules souches modifiées et procédés pour les utiliser
IL277878A (en) Preparations and methods for stem cell transplantation
EP3426268A4 (fr) Cellules souches pancréatiques et leurs utilisations
EP3288570A4 (fr) Cellules souches modifiées et leurs utilisations
GB201805287D0 (en) Haematoietic stem cell treatment
EP3865571A4 (fr) Cellules souches mésenchymateuses dérivées de la synoviale et leur utilisation
PL3833756T3 (pl) Enzymy epimerazy i ich zastosowanie
EP3680324A4 (fr) Cellules souches émanant de jeunes porcs et leur procédé de préparation
EP3866816A4 (fr) Exosomes issus de cellules souches mésenchymateuses et procédés